HOME >> BIOLOGY >> NEWS
Pain killer fights breast cancer by targeting key enzyme

A painkilling medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.

The drug is called nimesulide. In laboratory experiments on breast cancer cells, scientists found that derivatives of nimesulide stopped the production of aromatase, the enzyme implicated in estrogen-dependent breast cancer. This form of breast cancer is the most common kind of breast cancer in postmenopausal women.

Aromatase converts hormones called androgens into estrogens, such as the hormone estradiol. Estrogen is a powerful mitogen an agent that causes cells to divide, and too much estrogen can cause cells to divide too quickly.

While many women with estrogen-dependent breast cancer take aromatase inhibitors to control their disease, the problem is that the current inhibitor drugs halt estrogen production throughout the body, said Robert Brueggemeier, a study co-author and a professor of medicinal chemistry and pharmacognosy and dean of the College of Pharmacy at Ohio State University.

"That means that other tissues, like bone and brain, which rely on normal aromatase production, may suffer," he said. "For one, we think that aromatase helps to maintain bone tissue throughout the postmenopausal period. Current aromatase inhibitors may disturb normal bone production there is some suggestion that these drugs may increase the risk of fractures."

The study's results suggest that nimesulide may block aromatase production only in breast tissue. Nimesulide is a non-steroidal anti-inflammatory drug (NSAID), a drug that controls pain and inflammation. Studies of other NSAIDs, such as ibuprofen, have suggested that NSAIDs may reduce breast cancer incidence by 40 percent.

However, these drugs tend to halt aromatase production throughout the body.

Brueggemeier presented the work with Bin Su and Serena Landini, both graduate students in Ohio State's pharmacy pr
'"/>

Contact: Robert Brueggemeier
Brueggemeier.1@osu.edu
614-614-292-5711
Ohio State University
29-Mar-2006


Page: 1 2 3

Related biology news :

1. Aphids make chemical weapons to fight off killer ladybirds
2. Revealed -- Mosquito genes that could be controlling the spread of killer viruses
3. Common cancer gene sends death order to tiny killer
4. Bacteria show promise in fending off global amphibian killer
5. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
6. Veterinary scientists explore poultry virus as cancer killer
7. Turning a cellular sentinel into a cancer killer
8. Cellular killer also important to memory
9. Painkillers may threaten power of vaccines
10. A new target for painkillers
11. Hope for major advance in fighting world killer disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... ... , ... Lajollacooks4u is delighted to announce it has been named as one ... given only to businesses that have achieved consistently outstanding traveler reviews on TripAdvisor, as ... To qualify for the Certificate of Excellence –- an award that only 10 percent ...
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers from Ambry Genetics ... significant differences in the prevalence of hereditary genetic mutations, also called germline mutations, ... women. Results will be presented at the 2019 American Society of Clinical Oncology ...
(Date:5/26/2019)... ... ... Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used to treat spinal muscular atrophy ... by the Food and Drug Administration today. , The treatment is now ... United States and the second-ever approved treatment for SMA. , FDA granted priority review ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell ... of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical ... IND is the first of several planned clinical trials which will enable qualified PSC-enrolled ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... Clinic, a national leader in opioid treatment, announced today they are partnering to ... , Mytonomy recently deployed its virtual care platform at the Mayo Clinic to ...
(Date:5/31/2019)... City, California (PRWEB) , ... ... ... allowance of our patent applications from the USPTO providing proprietary interest to ... AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights ...
(Date:5/21/2019)... ABABA, Ethiopia (PRWEB) , ... May 21, 2019 ... ... für Brauerei in Berlin (VLB) today officially opened the inaugural Africa Brewing Conference ... brewing and malting industry in Africa. The event, which is supported through a ...
Breaking Biology Technology:
Cached News: